

TGFB2 and *BCL2L1* methylation in male laryngeal cancer patients

ZHISEN SHEN^{1*}, XIAOYING CHEN^{2*}, QUN LI^{1,2}, HUADAN YE²,
JINYUN LI², CHONGCHANG ZHOU^{1,2} and SHIWEI DUAN²

¹Department of Otorhinolaryngology, Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315040;

²Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University,
Ningbo, Zhejiang 315211, P.R. China

Received May 4, 2015; Accepted June 10, 2016

DOI: 10.3892/ol.2016.5018

Abstract. DNA methylation is a major regulatory mechanism of gene expression. The aim of the present study was to test the association of transforming growth factor β 2 (*TGFB2*) and B cell lymphoma 2-like 11 (*BCL2L1*) gene methylation with the risk of laryngeal squamous cell carcinoma (LSCC). Using bisulfite pyrosequencing technology, DNA methylation levels of *TGFB2* promoter and *BCL2L1* gene-body CpG cytosines were measured in 90 LSCC tissues and 90 adjacent normal tissues. Analysis of variance and paired sample t-test were used to determine the association of gene methylation and the risk of LSCC. Our results revealed that there were no differences in *TGFB2* and *BCL2L1* methylation levels between the LSCC tissues and the paired normal tissues ($P>0.05$). Further breakdown analyses demonstrated that the association results of the two gene methylation levels and LSCC remained unchanged with the age, smoking history, histological differentiation or clinical stage of the LSCC patients (all adjusted $P>0.05$). In conclusion, there is no association of *TGFB2* promoter and *BCL2L1* gene-body methylation with the risk of LSCC in males.

Introduction

Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck cancer in the world (1). The

incidence of LSCC in China has exhibited an increasing trend in the young population (2,3). LSCC is a complex disease, and it is hypothesized that both genetic and environmental factors play a role in it (4). Epigenetic modifications, including DNA methylation, are known as the bridging factors of genetics and the environment (5). However, the role of epigenetic modifications in the pathogenesis and progression of LSCC remains to be explained.

DNA methylation of CpG islands (CGIs) is a significant regulatory mechanism of gene expression (6). Epigenetic silencing of tumor suppressor genes by promoter hypermethylation is considered to be a significant event in the progression of cancers including leukemia (7), lung cancer (8) and prostate cancer (9). Gene-body methylation levels are also demonstrated to be correlated with gene expression (10,11).

TGFB2 is a member of the transforming growth factor β (TGFB) family, which encodes multifunctional peptides in the regulation of cell proliferation, differentiation, adhesion and migration (12). TGFB is able to inhibit tumor growth at the early stages and promote tumor growth at the late stages of disease (13). A previous study has demonstrated that increased *TGFB2* promoter methylation level is associated with prostate cancer progression (14). *BCL2L1* encodes a member of the BCL-2 (B cell lymphoma 2) protein family, which acts as an apoptotic activator that is involved in a wide variety of cellular activities (15). *BCL2L1* methylation has been noted to be associated with the risk of hematological and epithelial cancers (16).

In the current study, the methylation levels of *TGFB2* and *BCL2L1* were investigated in male laryngeal cancer patients to determine whether these epigenetic markers are associated with LSCC risk.

Materials and methods

Tissue samples. LSCC and adjacent tissues were collected from 90 male patients (mean age, 60.5 ± 8.65 years) who had undergone surgical treatment at the Department of Otolaryngology at Ningbo Lihuili Hospital, Zhejiang, China. The 90 tumors consisted of 43 well-differentiated cases, 32 moderately differentiated cases and 15 poorly differentiated cases. Among the LSCC patients, there were 27 stage I, 14 stage II, 11 stage III

Correspondence to: Dr Zhisen Shen, Department of Otorhinolaryngology, Lihuili Hospital of Ningbo University, 57 Xingning Road, Ningbo, Zhejiang 315040, P.R. China
E-mail: szs7216@163.com

Dr Shiwei Duan, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo, Zhejiang 315211, P.R. China
E-mail: duanshiwei@nbu.edu.cn

*Contributed equally

Key words: laryngeal cancer, transforming growth factor β 2, B cell lymphoma 2-like 11, DNA methylation, male




Figure 1. CpG islands (CGIs) within the transforming growth factor β 2 (*TGFB2*) promoter and B cell lymphoma 2-like 11 (*BCL2L1*) gene-body. (A) Eight CpG dinucleotides within *TGFB2*; (B) Six CpG dinucleotides within *BCL2L1*. F, forward primer; S, sequencing primer; R, reverse primer.

and 38 stage IV patients. All specimens were obtained freshly during the surgery and stored at -80°C . Permission was obtained from the bioethics committee at Ningbo Lihuili Hospital. All patients signed informed consent forms.

DNA bisulfite treatment and pyrosequencing analysis. Genomic DNA was isolated from tumor samples and then quantified as previously described (11,17). *TGFB2* and *BCL2L1* methylation levels were measured using bisulfite pyrosequencing technology. DNA conversion was performed using reagents provided in the Zymo EZ DNA Methylation-Gold kit (Zymo Research, Orange, CA, USA). The pyrosequencing procedures were performed as described previously (11,17). The primer sequences of *TGFB2* were 5'-GAGTAATTTTAAGTTGGGGAGAAGTTAGT-3' for the forward primer, 5'-Biotin-ACTCCAAACCCCAACCAACCA-3' for the reverse primer, and 5'-CCAACCAACCACAA-3' for the sequencing primer. The primer sequences of *BCL2L1* were 5'-GAGGAAGTTGTTGGAGGAGAAT-3' for the forward primer, 5'-Biotin-ACCCTACCCATCCCTATAC-3' for the reverse primer, and 5'-ATCCCCAAACCAAT-3' for the sequencing primer.

Statistical analyses. Statistical analyses were performed by PASW Statistics 18.0 software (SPSS Inc., Chicago, IL, USA). Logarithmic transformation was applied for the data deviated from normality. Analysis of variance was used to evaluate the association between the risk factors (age, smoking history, histological differentiation and clinical stage) and relative methylation rate difference. A paired sample *t*-test was applied to compare *TGFB2* and *BCL2L1* methylation between the

LSCC and adjacent tissues. All *P*-values were adjusted by logistic regression. A two-tailed $P < 0.05$ was considered to indicate a statistically significant difference. All figures were drawn using GraphPad Prism 6 software (GraphPad, San Diego, CA, USA).

Results

In the present study, we assessed the *TGFB2* and *BCL2L1* methylation levels in LSCC and their adjacent non-neoplastic tissues using bisulfite pyrosequencing technology. As shown in Fig. 1, the tested fragments were located in the CGIs of the *TGFB2* promoter (chr1:218519058-218519113) and *BCL2L1* gene-body (chr2:111879764-111879817). A total of eight and six CpG dinucleotides were measured for *TGFB2* and *BCL2L1*, respectively. The mean methylation levels of the tested CpG sites were used to compare their differences between the LSCC tumor and the adjacent normal tissues.

Our results revealed that there were no statistically significant differences of the methylation levels of *TGFB2* promoter (Fig. 2, $P = 0.653$) and *BCL2L1* gene-body (Fig. 3, $P = 0.311$) between LSCC tissues and the paired normal tissues. Further tests demonstrated no change in the results when adjusted for age, smoking history, histological differentiation and clinical stage (all adjusted $P > 0.05$). Moreover, there was no difference in the *TGFB2* promoter or *BCL2L1* gene-body methylation levels between tumor tissues and paired normal tissues in the breakdown analyses by age, smoking history, histological differentiation or clinical stage of the patients (Figs. 2 and 3, all $P > 0.05$, data not shown).




Figure 2. Comparisons of mean methylation level of transforming growth factor $\beta 2$ (*TGF β 2*) gene between tumor tissues and paired adjacent normal tissues. (A) Subgroup tests by age or smoking history; (B) Subgroup tests by histological differentiation; (C) Subgroup tests by clinical stage. T, tumor tissue; N, normal tissue. P^* , adjusted for age, smoking history, differentiation and stage.




Figure 3. Comparisons of transformed methylation level of B cell lymphoma 2-like 11 (*BCL2L11*) gene between tumor tissues and paired adjacent normal tissues. (A) Subgroup tests by age and smoking history; (B) Subgroup tests by histological differentiation; (C) Subgroup tests by clinical stage. T, tumor tissue; N, normal tissue. P^* , adjusted for age, smoking history, differentiation and stage.

Discussion

The aim of the present study was to determine whether DNA methylation of the *TGFB2* promoter and *BCL2L1* gene-body was associated with LSCC risk. Through a series of statistical analyses of these two genes, no clear correlation with laryngeal cancer was observed. Further subgroup tests by age, smoking history, histological differentiation and clinical stage also produced similar results.

Epigenetic modifications are central to tumorigenesis (18). In cancer cells, global hypomethylation is accompanied by hypermethylation of certain gene promoter CGIs (6). DNA methylation of the gene promoter region leads to gene silencing by blocking the binding of transcription factors or methyl-binding proteins (6), while a positive correlation has been observed in a variety of human tissue types between gene-body methylation and gene expression (10,19). As for LSCC, aberrant DNA methylation of tumor suppressor genes, including *MGMT*, *CHD5*, *p16*, *p14*, *PTEN*, *MYCT1* and *FHIT*, has been reported (4,20–23). DNA methylation levels of the promoter and gene-body are relatively dynamic (24). However, there are no previous studies on gene-body methylation in LSCC.

TGFB2 promoter hypermethylation was first identified as a potential epigenetic marker of prostate cancer in whole genome methylation profiling studies (25). A previous study revealed that the gene suppression of *TGFB2* was not associated with DNA methylation but with chromatin remodeling in breast cancer tissue samples (26). In the present study, we did not observe any association between *TGFB2* methylation and LSCC, suggesting that there were other genetic or epigenetic modifications in LSCC.

The apoptosis-related gene *BCL2LL1* has been noted to be hypermethylated in colon cancer (27), hematological and epithelial cancers (16). In addition, low *BCL2LL1* expression in chronic myeloid leukemia was ascribed to *BCL2LL1* hypermethylation at the gene promoter (28). Due to the limitation of not identifying a suitable primer set to assess the promoter CGI of the *BCL2LL1* gene, we selected the CGI in the gene-body region as an alternative. Although our study did not identify any significant association with *BCL2LL1* gene-body methylation, the contribution of other CGIs to LSCC risk remains to be explored.

In conclusion, our study suggests a lack of contribution of the *TGFB2* promoter and *BCL2LL1* gene-body methylation to LSCC in male patients. However, this study was designed as a pilot study, and further investigations are required to confirm our findings.

Acknowledgements

The study was supported by grants from Zhejiang Provincial Natural Science Foundation of China (no. LY14H160003), the Scientific Innovation Team Project of Ningbo (no. 2012B2019), Ningbo Social Development Key Research Project (no. 2012C5015), Ningbo Natural Science Foundation (no. 2012A610208, 2012A610217 and 2013A610217), the Medical and Health Research Project of Zhejiang Province (no. 2012ZDA042) and the Medical and Health Training Project of Zhejiang Province (no. 2014PYA 017).

References

- Morshed K, Polz-Dacewicz M, Szymański M and Polz D: Short-fragment PCR assay for highly sensitive broad-spectrum detection of human papillomaviruses in laryngeal squamous cell carcinoma and normal mucosa: clinico-pathological evaluation. *Eur Arch Otorhinolaryngology* 265 (Suppl 1): S89-S96, 2008.
- Chen K, Song F, He M, Li H, Qian B, Zhang W, Wei Q and Hao X: Trends in head and neck cancer incidence in Tianjin, China, between 1981 and 2002. *Head Neck* 31: 175-182, 2009.
- Cattaruzza MS, Maisonneuve P and Boyle P: Epidemiology of laryngeal cancer. *Eur J Cancer B Oral Oncol* 32B: 293-305, 1996.
- Yang M, Li W, Liu YY, Fu S, Qiu GB, Sun KL and Fu WN: Promoter hypermethylation-induced transcriptional down-regulation of the gene *MYCT1* in laryngeal squamous cell carcinoma. *BMC Cancer* 12: 219, 2012.
- Toporcov TN, Znaor A, Zhang ZF, Yu GP, Winn DM, Wei Q, Vilensky M, Vaughan T, Thomson P, Talamini R, *et al*: Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. *Int J Epidemiol* 44: 169-185, 2015.
- Laird PW: Cancer epigenetics. *Hum Mol Genet* 14: R65-R76, 2005.
- Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li Y, Xu C, Ouyang G and Duan S: The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. *PLoS One* 9: e96822, 2014.
- Huang T, Chen X, Hong Q, Deng Z, Ma H, Xin Y, Fang Y, Ye H, Wang R, Zhang C, *et al*: Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. *Sci Rep* 5: 8897, 2015.
- Jiang D, Shen Y, Dai D, Xu Y, Xu C, Zhu H, Huang T and Duan S: Meta-analyses of methylation markers for prostate cancer. *Tumour Biol* 35: 10449-10455, 2014.
- Aran D, Toperoff G, Rosenberg M and Hellman A: Replication timing-related and gene body-specific methylation of active human genes. *Hum Mol Genet* 20: 670-680, 2011.
- Xu L, Zheng D, Wang L, Jiang D, Liu H, Xu L, Liao Q, Zhang L, Liu P, Shi X, *et al*: GSK gene-body hypomethylation is associated with the risk of coronary heart disease. *Biomed Res Int* 2014: 151723, 2014.
- Sporn MB and Roberts AB: Transforming growth factor-beta: recent progress and new challenges. *J Cell Biol* 119: 1017-1021, 1992.
- Bierie B and Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. *Nat Rev Cancer* 6: 506-520, 2006.
- Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozelik H, Fleshner NE, Briollais L, van der Kwast TH and Bapat B: Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. *Int J Cancer* 129: 2454-2462, 2011.
- Leo E, Mancini M, Aluigi M, Castagnetti F, Martinelli G, Barbieri E and Santucci MA: DNA hypermethylation promotes the low expression of pro-apoptotic *BCL2L1* associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia. *Br J Haematol* 159: 373-376, 2012.
- Dunwell T, Hesson L, Rauch TA, Wang L, Clark RE, Dallol A, Gentle D, Catchpole D, Maher ER, Pfeifer GP and Latif F: A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. *Mol Cancer* 9: 44, 2010.
- Tang L, Ye H, Hong Q, Wang L, Wang Q, Wang H, Xu L, Bu S, Zhang L, Cheng J, *et al*: Elevated CpG island methylation of GSK gene predicts the risk of type 2 diabetes in Chinese males. *Gene* 547: 329-333, 2014.
- Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, Susini C, Cordelier P and Buscail L: Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. *Endocrinology* 149: 3137-3147, 2008.
- Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ and Church GM: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. *Nat Biotechnol* 27: 361-368, 2009.
- Yang J, Zhu XB, He LX, Gu ZW, Jin MZ and Ji WY: Clinical significance of epigenetic silencing and re-expression of O6-methylguanine-DNA methyltransferase using epigenetic agents in laryngeal carcinoma. *Oncol Lett* 9: 35-42, 2015.

21. Kis A, Tatár TZ, Gáll T, Boda R, Tar I, Major T, Redl P, Gergely L and Szarka K: Frequency of genetic and epigenetic alterations of p14ARF and p16INK4A in head and neck cancer in a Hungarian population. *Pathol Oncol Res* 20: 923-929, 2014.
22. Wang J, Chen H, Fu S, Xu ZM, Sun KL and Fu WN: The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. *Oral Oncol* 47: 601-608, 2011.
23. Yin D and Dong M: Methylation of promoter and expression of FHIT gene in laryngeal squamous cell carcinoma. *Lin Chuang Er Bi Yan Hou Ke Za Zhi* 19: 253-255, 258, 2005 (In Chinese).
24. Suzuki MM and Bird A: DNA methylation landscapes: provocative insights from epigenomics. *Nat Rev Genet* 9: 465-476, 2008.
25. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T and Bapat B: Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. *PloS One* 4: e4830, 2009.
26. Hinshelwood RA, Huschtscha LI, Melki J, Stirzaker C, Abdipranoto A, Vissel B, Ravasi T, Wells CA, Hume DA, Reddel RR and Clark SJ: Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. *Cancer Res* 67: 11517-11527, 2007.
27. Cho Y, Turner ND, Davidson LA, Chapkin RS, Carroll RJ and Lupton JR: Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation. *Exp Biol Med (Maywood)* 239: 302-310, 2014.
28. San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, Cordeu L, Martín V, Arqueros V, Gárate L, Fresquet V, Cervantes F, Martínez-Climent JA, *et al*: Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. *Eur J Cancer* 45: 1877-1889, 2009.